

BLESTMcath

Intratracheal catheter

For less invasive administration of pulmonary surfactant


An innovative solution for fast,
effective mitigation of NRDS

What is NRDS?

Neonatal respiratory distress syndrome (NRDS) is an important clinical syndrome responsible for a high rate of mortality and morbidity in premature (less than 37 weeks of gestational age) infants⁸.

Surfactant is essential to normal lung function in babies¹⁰. NRDS is caused by a lack of, or dysfunction in, surfactant, the chemicals that line the lung air spaces and help keep the lung expanded¹⁰. Pulmonary surfactant is a lipoprotein complex responsible for preventing the collapse of alveoli and increasing lung compliance⁵.

The low survival rate of preterm neonates affected by this condition propelled researchers to mitigate this issue. The development of exogenous pulmonary surfactants such as BLES[®] is innovative science impacting the treatment of NRDS.



What is LISA/MIST?

The less invasive surfactant administration (LISA) / minimally invasive surfactant therapy (MIST) method uses a small diameter catheter inserted into the trachea to deliver exogenous pulmonary surfactant to a spontaneously breathing patient supported by continuous positive airway pressure (nCPAP).

LISA is intended for neonates ≥ 28 weeks gestation and/or ≥ 1000 grams. For non-spontaneous breathing patients please use the Intubate-Surfactant-Extubate (InSurE) technique.

- LISA reduces the necessity for intubation and mechanical ventilation^{7,11}.
- Meta-analyses have shown that LISA is superior to nCPAP alone or the InSurE technique in terms of avoidance of bronchopulmonary dysplasia (BPD) and intracranial hemorrhage (ICH)^{6,7}.
- Long-term follow-ups report better pulmonary function and neurocognitive outcomes⁶.


What is BLEScath™?

BLEScath® is intended for the administration of BLES® using the LISA technique for rescue treatment of infants suffering from NRDS^{3,4}.

Pivotal Benefits

BLEScath™ supports the LISA method of surfactant administration. The administration of surfactant via a thin catheter compared with an ETT is associated with a reduced risk of death or BPD¹. LISA may offer institutions cost savings by decreasing the need for ventilation, consumables, diagnostic procedures, and investigations⁶.

BLEScath™ is a user-friendly device for healthcare practitioners who are not familiar with intubation or the use of Magill forceps⁶. BLEScath™ is designed explicitly for administration of BLES®. BLES® has a relatively low viscosity formulation and has been tested to pass through the holes in the stylet's anchor at the proximal end of BLEScath™. Other surfactants have not been tested with BLEScath™⁴.



User-friendly, intratracheal insertion catheter without the need for Magill forceps.

The stylet allows the catheter to be bent into the user's preferred shape.

Stainless steel stylet is rigid yet flexible for ease of insertion.

Thin diameter 5Fr catheter maintains physiologic pharyngeal function.

Technical Specifications

Size	5 Fr
Length	205 mm

Material Specifications

- Latex Free
- Stainless Steel (SS)
- DEHP Free
- Radiopaque polyvinyl chloride (PVC)



BLEScath's™ stainless steel stylet keeps its desired shape and does not migrate during the procedure¹¹. The first of its kind. The integrated SS stylet is anchored and remains fixed in place.



BLES® has demonstrated success with LISA; research has shown successful administration of BLES® via LISA in 95.3% of patients².

Ordering Information

Each package contains one 5 Fr catheter with integrated SS stylet.

1 unit = 1 catheter

10 units per case

✉ info@blesbiochem.com

☎ +1-519-457-2537

📠 +1-519-457-7470

References

1. Abdel-Latif ME, Davis PG, Wheeler KI, De Paoli AG, Dargaville PA. Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome. *Cochrane Database of Systematic Reviews*. 2021;2021(5).
2. Bhattacharya S, Read B, McGovern E, da Silva O. High-volume surfactant administration using a minimally invasive technique: Experience from a Canadian neonatal intensive care unit. *Paediatrics & Child Health*. 2018;24(5):313-7.
3. BLES® Product Monograph, Jan 31, 2022.
4. BLEScath® Instructions for Use (IFU) MD0102A.
5. Griesse M. Pulmonary surfactant in health and human lung diseases: state of the art. *Eur Respir J*. 1999 Jun;13(6):1455-76.
6. Herting E, Härtel C, Göpel W. Less invasive surfactant administration. *Current Opinion in Pediatrics*. 2020;32(2):228-34.
7. Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, et al. Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study. *Journal of Perinatology*. 2022;
8. Najafian, B., Khosravi, M. H., Neonatal Respiratory Distress Syndrome: Things to Consider and Ways to Manage. In: Barria, R. M., editor. *Update on Critical Issues on Infant and Neonatal Care* [Internet]. London: IntechOpen; 2020
9. Nouraeyan N, Lambrinakos-Raymond A, Leone M, Sant'Anna G. Surfactant administration in neonates: A review of delivery methods. *Canadian journal of respiratory therapy: CJRT = Revue canadienne de la thérapie respiratoire: RCTR*. 2014;50(3):91-5.
10. Soll R, Özek E. Prophylactic animal derived surfactant extract for preventing morbidity and mortality in preterm infants. *Cochrane Database of Systematic Reviews* 1997, Issue 4.
11. Vento M, Bohlin K, Herting E, Roehr CC, Dargaville PA. Surfactant administration via thin catheter: A practical guide. *Neonatology*. 2019;116(3):211-26.

For more information please visit our website BLEScath.com

BLES
Biochemicals Inc.

BLES Biochemicals Inc.
60 Pacific Court, Unit 8
London, Ontario,
Canada N5V 3K4